NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, announced today that the Company has submitted a regulatory filing to expand the commercialization of its Hepatitis B Immunoglobulin product, or HBIG, in Sweden.
